Core Viewpoint - The article highlights the rise of Zhong Huijuan, the chairwoman of Hansoh Pharmaceutical, who has become China's richest woman with a wealth of 141 billion yuan, surpassing previous titleholder Zong Fuli of Wahaha Group. This wealth surge is attributed to the significant increase in Hansoh Pharmaceutical's market value, which has more than doubled within the year, reflecting the company's strategic shift towards innovative drugs and the overall boom in the innovative pharmaceutical sector [1][2][5]. Group 1: Wealth and Company Growth - Zhong Huijuan's wealth has increased by over 60 billion yuan this year, driven by Hansoh Pharmaceutical's market capitalization rising from approximately 90 billion HKD to over 200 billion HKD, marking a year-to-date increase of over 100% [2][12]. - The salary structure within the company shows that in 2024, Zhong Huijuan's salary is 11.93 million yuan, while her daughter Sun Yuan, an executive director, earns 19.04 million yuan, significantly higher than her husband Sun Piaoyang, who earns only 1.65 million yuan [6][7]. Group 2: Strategic Shift to Innovative Drugs - Hansoh Pharmaceutical has transitioned from a focus on generic drugs to innovative drugs, with the number of innovative drugs increasing from 1 in 2019 to 7 in 2022, and innovative drug revenue surpassing generic drug revenue for the first time, reaching 50.6% [12]. - The company has also engaged in strategic overseas licensing agreements, with a notable deal involving a targeted antibody-drug conjugate (ADC) that includes an upfront payment of 80 million USD and potential milestone payments totaling 1.45 billion USD [12]. Group 3: Compliance and Regulatory Challenges - Despite its success, Hansoh Pharmaceutical has faced scrutiny over compliance issues, including a significant fine of 25.54 million yuan for improper competition practices related to "kickback sales" [22][23]. - The company's sales and distribution expenses have consistently exceeded 3 billion yuan annually for seven years, raising concerns about its marketing practices and business model [19][20]. - Historical allegations of bribery and improper conduct have also surfaced, with past incidents involving the company's sales managers engaging in corrupt practices to secure business advantages [24].

数据显示，2024年，公司营业收入为8.6亿元，同比下降10.11%；归母净利润为0.52亿元，同比下降 35.3%。 费用方面，2022年-2024年公司销售费用分别为5.32亿元、4.38亿元、3.72亿元，销售费用率分别为 48.93%、45.86%、43.34%。同期申万中药分类下的企业销售费用率中位数分别为33.02%、33.39%、 33.33%；算数平均值分别为31.89%、32.22%、31.41%，新天药业销售费用率高于行业整体水平约10个 百分点。 据2024年年报显示，报告期内公司销售费用中的市场开发与推广费显著减少，由2023年的3.04亿元降低 至1.26亿元，但职工薪酬及福利由去年同期的5858.99万元大幅增至2024年的1.95亿元，同比增超 230%。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 近日，一则关于新天药业的举报信在网络中广泛流传。 举报信揭露，新天药业通过"向日葵联盟"APP伪造问卷调查（每例300元）、朵儿互联网医院支付高额 科普文章费用（单篇500元），组织虚假学术会议、超标支付讲课费（单场最高5000元）等方式向医生 行贿，并 ...